

Zelira Therapeutics Ltd

16:49 11 Aug 2020

Zelira Therapeutics set to roll-out products in more US states using licensing model

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) is set to extend the roll-out of its products to more US states in the world's largest cannabis market, following the successful launch in Pennsylvania and Louisiana.

The company said it had successfully launched licensing deals in different jurisdictions, undertaking seven deals, including two in the US, in the first seven months of this year.

Speaking at a Proactive medicinal cannabis webinar, managing director Dr Richard Hopkins said each licensing deal in the US would attract six-figure upfront licensing fees and double-digit royalties.

In Pennsylvania, the company has generated seven-digit revenue in the first year and in Louisiana, the company 'virtually has the whole state to ourselves'.

Corporate structure

Hopkins said the company had been structured in such a manner that its teams were split between US and non-US, to enable both teams to work in independent jurisdictions.

"It is a smart strategic move so we can ensure we can run both jurisdictions in parallel," he said, noting that the US was a huge market.

In the US, there are 4 million registered medical cannabis patients in a population of 330 million compared to 65,000 registered medical cannabis patients in Germany with a population of 83 million and 11,000 patients in Australia with a population of 25 million.


Hopkins noted that every market around the globe had been growing by triple digits.

Multiple products launches

Price: 0.099

Market Cap: \$117.35 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.14 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com


Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets.

action@proactiveinvestors.com.au

RICH PRODUCT PIPELINE LAUNCHING IN 2020

On-track to launch 5 products in 2020



The company is on track to launch five products in 2020, having already launched HOPE™ for Autism in US and targeting for its launch in the Australian market by the end of the third quarter this year. It plans to launch Hope in Germany and the UK in 2021.

Zenivol™ for Insomnia is targeted for launch, also by the end of the third quarter this year, in both the US and Australia, with 2021 launch dates planned for Germany and the UK.

Its Aged Disorder is set for launch in the US by the end of 2020 and is in collaboration with the Parkinson's Foundation in the US.

Hopkins said more information would be disclosed on its dermatology and chronic pain, both of which were targeted for launch in 2021 in the US.

He said: "We are excited about all of the products, and each of them has been positioned to meet an unmet medical need."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).